



1Fu 1614

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/508,841
Applicant: Yoo *et al.*
Filed: September 21, 2004
TC/A.AU.: 1614
Examiner: Sharon Latimer

Confirmation No.: 8952

Docket No.: 12462.105004 CMED004
Customer No.: 20786
Title: A Pharmaceutical Composition for Treatment of Wounds Containing Blood Plasma or Serum

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the accompanying Form PTO/SB/08A, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each of the cited references is enclosed with the exception of U.S. patents and U.S. patent publications. The Examiner's attention is also drawn to U.S.S.N. 11/210,619, filed August 23, 2005. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe that any fees are due because this paper is being submitted before the mailing of a first Office Action on the merits, as under 37 C.F.R. § 1.97(b)(3). However, should the Commissioner determine that fees are due, he is hereby authorized to charge such fees and to credit any overpayment to Deposit Account No. 11-0980.


Respectfully submitted,


Madeline I. Johnston, Ph.D. Esq.
Reg. No. 36,174

Dated: June 8, 2006
King & Spalding LLP
1180 Peachtree Street, 34th Floor
Atlanta, GA 30309-3521
Office: (404) 572-4600/ Fax: (404) 572-5134

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 8, 2006.


Diane M. Guilfooy

4112397_1.DOC



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2				Complete if Known	
				Application Number	10/508,841
				Filing Date	September 21, 2004
				First Named Inventor	Yoo et al.
				Group Art Unit	1614
				Examiner Name	Sharon Latimer
				Attorney Docket Number	12462.105004 CMED004

4112396_1.DOC

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	5,149,691	A	Rutherford et al.	09-22-1994	
	AB	5,183,805	A	Lee et al.	02-02-1993	
	AC	5,376,636	A	Rutherford et al.	12-27-1994	
	AD	5,731,298	A	Reinmuller	03-24-1998	
	AE	5,897,880	A	Drizen et al.	04-27-1999	
	AF	5,981,606	A	Martin	11-09-1999	
	AG	6,048,844	A	Falk et al.	04-11-2000	
	AH	6,165,978	A	Rodgers et al.,	12-26-2000	
	AI	2003-0180390	A	Keum et al.	09-25-2003	
	AJ	2004-0019011	A	Falk et al.	01-29-2004	
	AK	2005-0136126	A	Keum et al.	02-23-2005	

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear
		Office ³	Number	Kind Code ² (if known)		
	AL	EP	0,493,985	A1	Johnson & Johnson	07-08-1992
	AM	WO	96/30038	A1	Rockefeller University	10-03-1996
	AN	WO	02/30432	A1	Medigenes	04-18-2002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	AO	ALLGÖWER, M., and HULLIGER, L., “Origin of fibroblasts from mononuclear blood cells: A study on in vitro formation of the collagen precursor, hydroxyproline, in buffy coat cultures,” <i>Surgery</i> , 47(4):603-610 (April 1960)		
	AP	ANONYMOUS, “Becaplermin Product Approval Information -- Licensing Action,” U.S. Food & Drug Administration, http://www.fda.gov/cder/biologics/products/becaomj121697.htm .		
	AQ	ANONYMOUS, “Becaplermin,” Medline Plus, www.nlm.nih.gov/medlineplus/druginfo/medmaster/a699049.html .		
	AR	DiCORLETO, P.E., and BOWEN-POPE, D.F., “Cultured endothelial cells produce a platelet-derived growth factor-like protein,” <i>Proc. Natl. Acad. Sci. USA</i> , 80(7):1919-1923 (April 1983).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/508,841
Sheet 2 of 2				Filing Date	September 21, 2004
				First Named Inventor	Yoo et al.
				Group Art Unit	1614
				Examiner Name	Sharon Latimer
				Attorney Docket Number	12462.105004 CMED004

4112396_1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁶
	BA	GREENHALGH, D.G., "The role of growth factors in wound healing," <i>J. Trauma</i> , 41(1):159-167 (July 1996).	
	BB	HOUCK, J.C., et al., "Induction of collagenolytic and proteolytic activities by anti-inflammatory drugs in the skin and fibroblast," <i>Biochem. Pharmacol.</i> , 17(10), 2081-2090 (October 1968).	
	BC	NISHIDA, T., et al., "Fibronectin: A new therapy for corneal trophic ulcer," <i>Arch. Ophthalmol.</i> , 101(7):1046-1048 (July 1983).	
	BD	WYSOCKI, A., et al., "Topical fibronectin therapy for treatment of a patient with chronic stasis ulcers," <i>Arch. Dermatol.</i> , 124(2):175-177 (February 1988).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.